Alterity Therapeutics (ATHE) Common Equity (2009 - 2025)

Alterity Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $35.6 million for Q4 2025.

• In Q4 2025, Common Equity rose 599.79% year-over-year to $35.6 million; the TTM figure through Dec 2025 stood at $35.6 million (up 599.79% YoY), while the FY2025 annual figure was $27.2 million, up 110.31% from the prior year.
• Common Equity was $35.6 million for Q4 2025 at Alterity Therapeutics, up from $27.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $35.6 million in Q4 2025 to a low of $5.1 million in Q4 2024.
• Historically, Common Equity has averaged $20.1 million across 5 years, with a median of $21.0 million in 2021.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 55.62% in 2024, then soared 599.79% in 2025.
• A 5-year view of Common Equity shows it stood at $30.0 million in 2021, then sank by 38.37% to $18.5 million in 2022, then slumped by 37.87% to $11.5 million in 2023, then sank by 55.62% to $5.1 million in 2024, then jumped by 599.79% to $35.6 million in 2025.
• The last three Common Equity figures came in at $35.6 million (Q4 2025), $27.2 million (Q2 2025), and $5.1 million (Q4 2024), per Business Quant data.